Limb-Girdle Muscular Dystrophy Scientific Leaders - Together With the FDA - Will Come Together for a Drug Development Workshop on February 8, 2024
13 Dec 2023
ROCKVILLE, Md., Dec. 13, 2023 /PRNewswire/ -- On February 8, 2024, The Speak Foundation, a patient-led 501(c)(3) organization for Limb-Girdle Muscular Dystrophy (LGMD), will be convening a multi-stakeholder LGMD Scientific Drug Development Workshop in Rockville, Maryland. The workshop will continue to drive the momentum for the sense of urgency needed by the patient community to accelerate LGMD drug development.
Continue Reading
Preview
Source: PRNewswire
LGMD Scientific Drug Development Workshop
Preview
Source: PRNewswire
The Speak Foundation logo
Academic medical experts, senior leaders from the U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER), highly experienced drug developers, and other specialists will come together to discuss LGMD pathophysiology, clinical outcomes and patient-focused drug development, surrogate endpoints and the accelerated approval pathway. The meeting will focus on six LGMD subtypes: LGMD2A/R1, LGMD2B/R2, LGMD2C/R3, LGMD2D/R4, LGMD2E/R5, and LGMD2I/R9.
"In September 2022, at the LGMD community's first Externally-Led Patient Focused Drug Development Meeting (EL-PFDD), the FDA heard perspectives of patients and caregivers on the health effects, daily impacts, treatment goals, and decision factors that would be considered when seeking out or selecting a treatment," explains Kathryn Bryant, founder of the Speak Foundation. "This workshop is a continuing step to work with the FDA and LGMD scientific leaders on pushing critical drug development forward. The time is now."
LGMD Scientific Workshop session presenters will include CBER Director Dr. Peter Marks, and CDER's Office of New Drugs (OND) Director, Dr. Peter Stein. Other confirmed speakers include Dr. Jerry R. Mendell, retired attending neurologist of Nationwide Children's Hospital, Dr. Nicholas Johnson of Virginia Commonwealth University, Dr. Louise Rodino-Klapac of Sarepta Therapeutics, Dr. Douglas Sproule of ML Bio Solutions, a BridgeBio affiliate, Dr. Katherine Mathews of University of Iowa Health Care, Dr. Matthew Wicklund of University of Texas San Antonio, Dr. Peter Kang of University of Minnesota Medical School and Dr. Lindsay Alfano of Nationwide Children's Hospital.
"As a translational clinician scientist, devoting a lifetime of work toward improving the lives of patients with muscular dystrophy, workshops like the LGMD Scientific meeting are important venues for discussing the current scientific understanding of LGMD and the implications for drug development." said Dr. Jerry R. Mendell. "Bringing key LGMD stakeholders together to share ideas and research findings in a public forum is the most productive way to find solutions and advance therapies that will improve the lives of LGMD patients."
The LGMD Scientific Workshop will be a focused discussion with clinicians, scientific researchers, drug developers, regulators, patients and patient advocates on the characteristics of LGMD that drive drug development programs. The meeting will be held virtually and by invitation for in-person attendance. Proceedings will be recorded and shared with the broader patient and scientific communities through The Speak Foundation. More details will be added soon to: The Speak Foundation - Limb Girdle Muscular Dystrophy.
About The Speak Foundation:
The Speak Foundation is a 501(c)(3) nonprofit charity, which is focused on supporting patients living with all forms of LGMD and on facilitating development of treatments for these diseases.
Limb-Girdle Muscular Dystrophy (LGMD) is a group of muscular dystrophies caused by mutations in one of over 30 genes. The age of onset, symptoms, progression, and inheritance pattern varies among genetic subtypes, but generally result in severe disability and are often life-threatening due to cardiac and respiratory complications. There are estimated to be some 20,000+ people living with a form LGMD in the United States.
Media Contact:
Rachel DeConti
[email protected]
860-209-0492
SOURCE The Speak Foundation
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.